Method and apparatus for providing dynamic multi-stage signal amplification in a medical device

Information

  • Patent Grant
  • 10194846
  • Patent Number
    10,194,846
  • Date Filed
    Friday, August 25, 2017
    7 years ago
  • Date Issued
    Tuesday, February 5, 2019
    5 years ago
Abstract
Methods and apparatus for providing multi-stage signal amplification in a medical telemetry system are provided.
Description
BACKGROUND

Analyte (e.g., glucose) monitoring systems including continuous and discrete monitoring systems generally include a small, lightweight battery powered and microprocessor controlled system which is configured to detect signals proportional to the corresponding measured glucose levels using an electrometer, and RF signals to transmit the collected data. One aspect of certain analyte monitoring systems include a transcutaneous or subcutaneous analyte sensor configuration which is, for example, partially mounted on the skin of a subject whose analyte level is to be monitored. The sensor cell may use a two or three-electrode (work, reference and counter electrodes) configuration driven by a controlled potential (potentiostat) analog circuit connected through a contact system.


The analyte sensor may be configured so that a portion thereof is placed under the skin of the patient so as to detect the analyte levels of the patient, and another portion of segment of the analyte sensor that is in communication with the transmitter unit. The transmitter unit is configured to transmit the analyte levels detected by the sensor over a wireless communication link such as an RF (radio frequency) communication link to a receiver/monitor unit. The receiver/monitor unit performs data analysis, among others on the received analyte levels to generate information pertaining to the monitored analyte levels. To provide flexibility in analyte sensor manufacturing and/or design, among others, tolerance of a larger range of the analyte sensor sensitivities for processing by the transmitter unit is desirable.


In view of the foregoing, it would be desirable to have a method and apparatus for providing a dynamic multi-stage amplification of signals for use in medical telemetry systems such as, for example, analyte monitoring systems.


SUMMARY OF THE INVENTION

In one embodiment, an apparatus including a first amplifier having at least one input terminal and an output terminal, the at least one input terminal coupled to a signal source, the output terminal configured to provide a first output signal, a second amplifier having at least one input terminal and an output terminal, the at least one input terminal coupled to the output terminal of the first amplifier, the output terminal of the second amplifier configured to provide a second output signal, a processor operatively coupled to receive the first output signal and the second output signal, where the first output signal is a predetermined ratio of the second output signal, and further, where the first output signal and the second output signal are associated with a monitored analyte level of a user is disclosed.


These and other objects, features and advantages of the present invention will become more fully apparent from the following detailed description of the embodiments, the appended claims and the accompanying drawings.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 illustrates a block diagram of a data monitoring and management system for practicing one or more embodiments of the present invention;



FIG. 2 is a block diagram of the transmitter unit of the data monitoring and management system shown in FIG. 1 in accordance with one embodiment of the present invention;



FIG. 3 is a block diagram of the receiver/monitor unit of the data monitoring and management system shown in FIG. 1 in accordance with one embodiment of the present invention; and



FIG. 4 is a schematic of the dynamic multi-stage signal amplification in the transmitter unit of the data monitoring and management system shown in FIG. 1 in accordance with one embodiment of the present invention.





DETAILED DESCRIPTION

As described in further detail below, in accordance with the various embodiments of the present invention, there is provided a method and apparatus for providing dynamic multi-stage signal amplification for use in a medical telemetry system. In particular, within the scope of the present invention, there are provided method and apparatus for a multi-stage signal amplifier configuration in the analog interface of the data transmitter unit in the data processing and management system.



FIG. 1 illustrates a data monitoring and management system such as, for example, analyte (e.g., glucose) monitoring system 100 in accordance with one embodiment of the present invention. The subject invention is further described primarily with respect to a glucose monitoring system for convenience and such description is in no way intended to limit the scope of the invention. It is to be understood that the analyte monitoring system may be configured to monitor a variety of analytes, e.g., lactate, and the like.


Analytes that may be monitored include, for example, acetyl choline, amylase, bilirubin, cholesterol, chorionic gonadotropin, creatine kinase (e.g., CK-MB), creatine, DNA, fructosamine, glucose, glutamine, growth hormones, hormones, ketones, lactate, peroxide, prostate-specific antigen, prothrombin, RNA, thyroid stimulating hormone, and troponin. The concentration of drugs, such as, for example, antibiotics (e.g., gentamicin, vancomycin, and the like), digitoxin, digoxin, drugs of abuse, theophylline, and warfarin, may also be monitored.


The analyte monitoring system 100 includes a sensor 101, a transmitter unit 102 coupled to the sensor 101, and a primary receiver unit 104 which is configured to communicate with the transmitter unit 102 via a communication link 103. The primary receiver unit 104 may be further configured to transmit data to a data processing terminal 105 for evaluating the data received by the primary receiver unit 104. Moreover, the data processing terminal in one embodiment may be configured to receive data directly from the transmitter unit 102 via a communication link which may optionally be configured for bi-directional communication.


Also shown in FIG. 1 is a secondary receiver unit 106 which is operatively coupled to the communication link and configured to receive data transmitted from the transmitter unit 102. Moreover, as shown in the Figure, the secondary receiver unit 106 is configured to communicate with the primary receiver unit 104 as well as the data processing terminal 105. Indeed, the secondary receiver unit 106 may be configured for bi-directional wireless communication with each of the primary receiver unit 104 and the data processing terminal 105. As discussed in further detail below, in one embodiment of the present invention, the secondary receiver unit 106 may be configured to include a limited number of functions and features as compared with the primary receiver unit 104. As such, the secondary receiver unit 106 may be configured substantially in a smaller compact housing or embodied in a device such as a wrist watch, for example. Alternatively, the secondary receiver unit 106 may be configured with the same or substantially similar functionality as the primary receiver unit 104, and may be configured to be used in conjunction with a docking cradle unit for placement by bedside, for night time monitoring, and/or bi-directional communication device.


Only one sensor 101, transmitter unit 102, communication link 103, and data processing terminal 105 are shown in the embodiment of the analyte monitoring system 100 illustrated in FIG. 1. However, it will be appreciated by one of ordinary skill in the art that the analyte monitoring system 100 may include one or more sensor 101, transmitter unit 102, communication link 103, and data processing terminal 105. Moreover, within the scope of the present invention, the analyte monitoring system 100 may be a continuous monitoring system, or semi-continuous, or a discrete monitoring system. In a multi-component environment, each device is configured to be uniquely identified by each of the other devices in the system so that communication conflict is readily resolved between the various components within the analyte monitoring system 100.


In one embodiment of the present invention, the sensor 101 is physically positioned in or on the body of a user whose analyte level is being monitored. The sensor 101 may be configured to continuously sample the analyte level of the user and convert the sampled analyte level into a corresponding data signal for transmission by the transmitter unit 102. In one embodiment, the transmitter unit 102 is coupled to the sensor 101 so that both devices are positioned on the user's body, with at least a portion of the analyte sensor 101 positioned transcutaneously under the skin layer of the user. The transmitter unit 102 performs data processing such as filtering and encoding on data signals, each of which corresponds to a sampled analyte level of the user, for transmission to the primary receiver unit 104 via the communication link 103.


In one embodiment, the analyte monitoring system 100 is configured as a one-way RF communication path from the transmitter unit 102 to the primary receiver unit 104. In such embodiment, the transmitter unit 102 transmits the sampled data signals received from the sensor 101 without acknowledgement from the primary receiver unit 104 that the transmitted sampled data signals have been received. For example, the transmitter unit 102 may be configured to transmit the encoded sampled data signals at a fixed rate (e.g., at one minute intervals) after the completion of the initial power on procedure. Likewise, the primary receiver unit 104 may be configured to detect such transmitted encoded sampled data signals at predetermined time intervals. Alternatively, the analyte monitoring system 100 may be configured with a bi-directional RF (or otherwise) communication between the transmitter unit 102 and the primary receiver unit 104.


Additionally, in one aspect, the primary receiver unit 104 may include two sections. The first section is an analog interface section that is configured to communicate with the transmitter unit 102 via the communication link 103. In one embodiment, the analog interface section may include an RF receiver and an antenna for receiving and amplifying the data signals from the transmitter unit 102, which are thereafter, demodulated with a local oscillator and filtered through a band-pass filter. The second section of the primary receiver unit 104 is a data processing section which is configured to process the data signals received from the transmitter unit 102 such as by performing data decoding, error detection and correction, data clock generation, and data bit recovery.


In operation, upon completing the power-on procedure, the primary receiver unit 104 is configured to detect the presence of the transmitter unit 102 within its range based on, for example, the strength of the detected data signals received from the transmitter unit 102 or a predetermined transmitter identification information. Upon successful synchronization with the corresponding transmitter unit 102, the primary receiver unit 104 is configured to begin receiving from the transmitter unit 102 data signals corresponding to the user's detected analyte level. More specifically, the primary receiver unit 104 in one embodiment is configured to perform synchronized time hopping with the corresponding synchronized transmitter unit 102 via the communication link 103 to obtain the user's detected analyte level.


Referring again to FIG. 1, the data processing terminal 105 may include a personal computer, a portable computer such as a laptop or a handheld device (e.g., personal digital assistants (PDAs)), and the like, each of which may be configured for data communication with the receiver via a wired or a wireless connection. Additionally, the data processing terminal 105 may further be connected to a data network (not shown) for storing, retrieving and updating data corresponding to the detected analyte level of the user.


Within the scope of the present invention, the data processing terminal 105 may include an infusion device such as an insulin infusion pump or the like, which may be configured to administer insulin to patients, and which may be configured to communicate with the receiver unit 104 for receiving, among others, the measured analyte level. Alternatively, the receiver unit 104 may be configured to integrate an infusion device therein so that the receiver unit 104 is configured to administer insulin therapy to patients, for example, for administering and modifying basal profiles, as well as for determining appropriate boluses for administration based on, among others, the detected analyte levels received from the transmitter unit 102.


Additionally, the transmitter unit 102, the primary receiver unit 104 and the data processing terminal 105 may each be configured for bi-directional wireless communication such that each of the transmitter unit 102, the primary receiver unit 104 and the data processing terminal 105 may be configured to communicate (that is, transmit data to and receive data from) with each other via the wireless communication link. More specifically, the data processing terminal 105 may in one embodiment be configured to receive data directly from the transmitter unit 102 via the communication link, where the communication link, as described above, may be configured for bi-directional communication.


In this embodiment, the data processing terminal 105 which may include an insulin pump, may be configured to receive the analyte signals from the transmitter unit 102, and thus, incorporate the functions of the receiver unit 104 including data processing for managing the patient's insulin therapy and analyte monitoring. In one embodiment, the communication link 103 may include one or more of an RF communication protocol, an infrared communication protocol, a Bluetooth® enabled communication protocol, an 802.11x wireless communication protocol, or an equivalent wireless communication protocol which would allow secure, wireless communication of several units (for example, per HIPAA requirements) while avoiding potential data collision and interference.



FIG. 2 is a block diagram of the transmitter of the data monitoring and detection system shown in FIG. 1 in accordance with one embodiment of the present invention. Referring to the Figure, the transmitter unit 102 in one embodiment includes an analog interface 201 configured to communicate with the sensor 101 (FIG. 1), a user input 202, and a temperature detection section 203, each of which is operatively coupled to a transmitter processor 204 such as a central processing unit (CPU). As can be seen from FIG. 2, there are provided four contacts, three of which are electrodes—work electrode (W) 210, guard contact (G) 211, reference electrode (R) 212, and counter electrode (C) 213, each operatively coupled to the analog interface 201 of the transmitter unit 102 for connection to the sensor 101 (FIG. 1). In one embodiment, each of the work electrode (W) 210, guard contact (G) 211, reference electrode (R) 212, and counter electrode (C) 213 may be made using a conductive material that is either printed or etched, for example, such as carbon which may be printed, or metal foil (e.g., gold) which may be etched. Moreover, in a further aspect, the electrode layers may be disposed in a stacked configuration where, each of the working electrode 210, the reference electrode 212 and the counter electrode 213 may be disposed on a substrate layer with one or more dielectric layers disposed therebetween such that at least a portion of each of the electrodes are positioned on top of one another in a stacked or layered configuration.


Further shown in FIG. 2 are a transmitter serial communication section 205 and an RF transmitter 206, each of which is also operatively coupled to the transmitter processor 204. Moreover, a power supply 207 such as a battery is also provided in the transmitter unit 102 to provide the necessary power for the transmitter unit 102. Additionally, as can be seen from the Figure, clock 208 is provided to, among others, supply real time information to the transmitter processor 204.


In one embodiment, a unidirectional input path is established from the sensor 101 (FIG. 1) and/or manufacturing and testing equipment to the analog interface 201 of the transmitter unit 102, while a unidirectional output is established from the output of the RF transmitter 206 of the transmitter unit 102 for transmission to the primary receiver unit 104. In this manner, a data path is shown in FIG. 2 between the aforementioned unidirectional input and output via a dedicated link 209 from the analog interface 201 to serial communication section 205, thereafter to the processor 204, and then to the RF transmitter 206. As such, in one embodiment, via the data path described above, the transmitter unit 102 is configured to transmit to the primary receiver unit 104 (FIG. 1), via the communication link 103 (FIG. 1), processed and encoded data signals received from the sensor 101 (FIG. 1). Additionally, the unidirectional communication data path between the analog interface 201 and the RF transmitter 206 discussed above allows for the configuration of the transmitter unit 102 for operation upon completion of the manufacturing process as well as for direct communication for diagnostic and testing purposes.


As discussed above, the transmitter processor 204 is configured to transmit control signals to the various sections of the transmitter unit 102 during the operation of the transmitter unit 102. In one embodiment, the transmitter processor 204 also includes a memory (not shown) for storing data such as the identification information for the transmitter unit 102, as well as the data signals received from the sensor 101. The stored information may be retrieved and processed for transmission to the primary receiver unit 104 under the control of the transmitter processor 204. Furthermore, the power supply 207 may include a commercially available battery.


The transmitter unit 102 is also configured such that the power supply section 207 is capable of providing power to the transmitter for a minimum of about three months of continuous operation after having been stored for about eighteen months in a low-power (non-operating) mode. In one embodiment, this may be achieved by the transmitter processor 204 operating in low power modes in the non-operating state, for example, drawing no more than approximately 1 μA of current. Indeed, in one embodiment, the final step during the manufacturing process of the transmitter unit 102 may place the transmitter unit 102 in the lower power, non-operating state (i.e., post-manufacture sleep mode). In this manner, the shelf life of the transmitter unit 102 may be significantly improved. Moreover, as shown in FIG. 2, while the power supply unit 207 is shown as coupled to the processor 204, and as such, the processor 204 is configured to provide control of the power supply unit 207, it should be noted that within the scope of the present invention, the power supply unit 207 is configured to provide the necessary power to each of the components of the transmitter unit 102 shown in FIG. 2.


Referring back to FIG. 2, the power supply section 207 of the transmitter unit 102 in one embodiment may include a rechargeable battery unit that may be recharged by a separate power supply recharging unit (for example, provided in the receiver unit 104) so that the transmitter unit 102 may be powered for a longer period of usage time. Moreover, in one embodiment, the transmitter unit 102 may be configured without a battery in the power supply section 207, in which case the transmitter unit 102 may be configured to receive power from an external power supply source (for example, a battery) as discussed in further detail below.


Referring yet again to FIG. 2, the temperature detection section 203 of the transmitter unit 102 is configured to monitor the temperature of the skin near the sensor insertion site. The temperature reading is used to adjust the analyte readings obtained from the analog interface 201. The RF transmitter 206 of the transmitter unit 102 may be configured for operation in the frequency band of 315 MHz to 322 MHz, for example, in the United States. Further, in one embodiment, the RF transmitter 206 is configured to modulate the carrier frequency by performing Frequency Shift Keying and Manchester encoding. In one embodiment, the data transmission rate is 19,200 symbols per second, with a minimum transmission range for communication with the primary receiver unit 104.


Referring yet again to FIG. 2, also shown is a leak detection circuit 214 coupled to the guard contact (G) 211 and the processor 204 in the transmitter unit 102 of the data monitoring and management system 100. The leak detection circuit 214 in accordance with one embodiment of the present invention may be configured to detect leakage current in the sensor 101 to determine whether the measured sensor data are corrupt or whether the measured data from the sensor 101 is accurate.


Additional detailed description of the continuous analyte monitoring system, its various components including the functional descriptions of the transmitter are provided in U.S. Pat. No. 6,175,752 issued Jan. 16, 2001 entitled “Analyte Monitoring Device and Methods of Use”, and in U.S. patent application Ser. No. 10/745,878 filed Dec. 26, 2003, now U.S. Pat. No. 7,811,231, entitled “Continuous Glucose Monitoring System and Methods of Use”, each assigned to the Assignee of the present application, the disclosure of each of which are incorporated herein by reference for all purposes.



FIG. 3 is a block diagram of the receiver/monitor unit of the data monitoring and management system shown in FIG. 1 in accordance with one embodiment of the present invention. Referring to FIG. 3, the primary receiver unit 104 includes a blood glucose test strip interface 301, an RF receiver 302, an input 303, a temperature detection section 304, and a clock 305, each of which is operatively coupled to a receiver processor 307. As can be further seen from the Figure, the primary receiver unit 104 also includes a power supply 306 operatively coupled to a power conversion and monitoring section 308. Further, the power conversion and monitoring section 308 is also coupled to the receiver processor 307. Moreover, also shown are a receiver serial communication section 309, and an output 310, each operatively coupled to the receiver processor 307.


In one embodiment, the test strip interface 301 includes a glucose level testing portion to receive a manual insertion of a glucose test strip, and thereby determine and display the glucose level of the test strip on the output 310 of the primary receiver unit 104. This manual testing of glucose can be used to calibrate sensor 101. The RF receiver 302 is configured to communicate, via the communication link 103 (FIG. 1) with the RF transmitter 206 of the transmitter unit 102, to receive encoded data signals from the transmitter unit 102 for, among others, signal mixing, demodulation, and other data processing. The input 303 of the primary receiver unit 104 is configured to allow the user to enter information into the primary receiver unit 104 as needed. In one aspect, the input 303 may include one or more keys of a keypad, a touch-sensitive screen, or a voice-activated input command unit. The temperature detection section 304 is configured to provide temperature information of the primary receiver unit 104 to the receiver processor 307, while the clock 305 provides, among others, real time information to the receiver processor 307.


Each of the various components of the primary receiver unit 104 shown in FIG. 3 is powered by the power supply 306 which, in one embodiment, includes a battery. Furthermore, the power conversion and monitoring section 308 is configured to monitor the power usage by the various components in the primary receiver unit 104 for effective power management and to alert the user, for example, in the event of power usage which renders the primary receiver unit 104 in sub-optimal operating conditions. An example of such sub-optimal operating condition may include, for example, operating the vibration output mode (as discussed below) for a period of time thus substantially draining the power supply 306 while the processor 307 (thus, the primary receiver unit 104) is turned on. Moreover, the power conversion and monitoring section 308 may additionally be configured to include a reverse polarity protection circuit such as a field effect transistor (FET) configured as a battery activated switch.


The serial communication section 309 in the primary receiver unit 104 is configured to provide a bi-directional communication path from the testing and/or manufacturing equipment for, among others, initialization, testing, and configuration of the primary receiver unit 104. Serial communication section 309 can also be used to upload data to a computer, such as time-stamped blood glucose data. The communication link with an external device (not shown) can be made, for example, by cable, infrared (IR) or RF link. The output 310 of the primary receiver unit 104 is configured to provide, among others, a graphical user interface (GUI) such as a liquid crystal display (LCD) for displaying information. Additionally, the output 310 may also include an integrated speaker for outputting audible signals as well as to provide vibration output as commonly found in handheld electronic devices, such as mobile telephones presently available. In a further embodiment, the primary receiver unit 104 also includes an electro-luminescent lamp configured to provide backlighting to the output 310 for output visual display in dark ambient surroundings.


Referring back to FIG. 3, the primary receiver unit 104 in one embodiment may also include a storage section such as a programmable, non-volatile memory device as part of the processor 307, or provided separately in the primary receiver unit 104, operatively coupled to the processor 307. The processor 307 is further configured to perform Manchester decoding as well as error detection and correction upon the encoded data signals received from the transmitter unit 102 via the communication link 103.


In a further embodiment, the one or more of the transmitter unit 102, the primary receiver unit 104, secondary receiver unit 106, or the data processing terminal/infusion section 105 may be configured to receive the blood glucose value wirelessly over a communication link from, for example, a glucose meter. In still a further embodiment, the user or patient manipulating or using the analyte monitoring system 100 (FIG. 1) may manually input the blood glucose value using, for example, a user interface (for example, a keyboard, keypad, and the like) incorporated in the one or more of the transmitter unit 102, the primary receiver unit 104, secondary receiver unit 106, or the data processing terminal/infusion section 105.



FIG. 4 is a schematic of the dynamic multi-stage signal amplification in the transmitter unit of the data monitoring and management system shown in FIG. 1 in accordance with one embodiment of the present invention. Referring to FIG. 4, there is provided in one embodiment a transimpedance amplifier 420 whose output terminal 423 is coupled to a first input terminal 411 of the analog to digital converter (ADC) 410 in the analog interface 201 (FIG. 2) of the transmitter unit 102. Further shown in FIG. 4, the monitored analyte sensor signal from the sensor 101 is provided to an inverting input terminal 421 of the transimpedance amplifier 420. The sensor signal in FIG. 4 is shown as a signal source 440. Also shown in FIG. 4 is resistor 460. Furthermore, a noninverting input terminal 422 of the transimpedance amplifier 420 is provided with a reference voltage signal from a reference signal source Vref 450. In one embodiment, the reference voltage signal may be approximately 1.012 volts. However, based upon the component tolerance, and design configuration, other suitable reference voltage signals may be used.


In one aspect, based on the input analyte sensor signal from the signal source 440 and the reference signal Vref 450, the transimpedance amplifier 420 may be in one embodiment configured to convert the received current signal representing the monitored or detected analyte level, and to convert the current signal to a corresponding voltage signal which is provided to the output terminal 423 of the transimpedance amplifier 420. Further, as shown in FIG. 4 the monitored analyte voltage signal from the output terminal 423 of the transimpedance amplifier 420 is provided to the first input terminal 411 (Channel 1) of the ADC 410.


Referring again to FIG. 4, a second amplifier 430 is provided in one embodiment whose noninverting input terminal 431 is coupled to the output terminal 423 of the transimpedance amplifier 420 to receive the output voltage signal corresponding to the monitored analyte level, while an inverting input terminal 432 of the second amplifier 430 is coupled in one embodiment to the reference signal Vref source 450. Moreover, output terminal 433 of the second amplifier is coupled in one embodiment to a second input terminal 412 (Channel 2) of the ADC 410. In operation, the second amplifier 430 may be configured to step up the output signal of the transimpedance amplifier 410 by a predetermined factor (for example, a factor of 2), and to provide the stepped up signal to the analog to digital converter (ADC) 410.


Referring back to FIG. 4, the analog to digital converter (ADC) 410 of the analog interface 201 (FIG. 2) of the transmitter unit 102 (FIG. 1) in one embodiment may be configured to detect signals at both the first and second input terminals or channels 411, 412, and based on one or more predetermined process or routine, the voltage signal at one of the first or the second input terminals or channels 411, 412 is used by the ADC 410 for further processing as corresponding to the monitored analyte level from the sensor 101 (FIG. 1). That is, in one embodiment, depending upon the signal resolution corresponding to the analyte level monitored, the ADC 410 may be configured to select one of the output signals from the transimpedance amplifier 420 or the second amplifier 430 for further processing.


For example, when the signal received at the second input terminal 412 of the ADC 410 exceeds a predetermined threshold value, the input signal at the first input terminal 411 may be used. More specifically, in one embodiment, the ADC 410 may be configured to process the signals at the second input terminal 412 (Channel 2) since it has a higher resolution compared to the signal at the first input terminal 411 received from the transimpedance amplifier 420. When the signal received at the second input terminal 412 exceeds a predetermined threshold level (for example, based on the tolerance level of the analog to digital converter (ADC) 410), the voltage signal received at the first input terminal 411 from the transimpedance amplifier 420 may be used to convert to a corresponding digital signal representing the monitored analyte level detected by the sensor 101 (FIG. 1).


Referring back to FIG. 4, in one embodiment, the analog to digital converter (ADC) 410 may include a 12 bit A/D converter configured to support up to approximately 4,096 bits or ADC counts. In this case, in one embodiment, when the signal at the second input terminal 412 of the ADC 410 approaches approximately 4,000 bits or ADC counts, for example, the processor 204 (FIG. 2) of the transmitter unit 102 may be configured to switch from the second input terminal 412 to the first input terminal 411, to use the output signal from the transimpedance amplifier 420. In this manner, in one embodiment, the processor 204 of the transmitter unit 102 may be configured to monitor the signal levels at the two input terminals 411, 412 of the ADC 410, and when the signal level or ADC count associated with the output signal from the second amplifier 430 provided at the second input terminal 412 of the ADC 410 exceeds the predetermined threshold (for example, 4,000 bits or ADC count), the processor 204 may be configured to switch over to the output signal of the transimpedance amplifier 410 provided on the first input terminal 411 of the ADC 410 for further processing.


In the manner described above, the dynamic multi-stage amplifier configuration in one embodiment may be configured to support variations in the analyte sensor sensitivities due to, for example, manufacturing variations, among others, while maintaining an acceptable or desirable sensor signal resolution. For example, in one embodiment, high sensitivity sensors may be configured for use with the full scale or range (for example, up to approximately 150 nA corresponding to the supported approximately 500 mg/dL glucose level) associated with the transimpedance amplifier 420 output signal provided to the first input terminal 411 (Channel 1) of the analog to digital converter (ADC) 410, while low sensitivity sensors may be associated with the second amplifier 430 output signal (for example, full scale current signal level of approximately 75 nA corresponding to the supported approximately 500 mg/dL glucose level) provided to the second input terminal 412 (Channel 2) of the analog to digital converter (ADC) 410.


For example, as discussed above, in one embodiment, the processor 204 of the transmitter unit 102 may be configured to monitor the signals at the two input terminals 411, 412 of the ADC 410, and determine, that if the received signal level does not have sufficient resolution to convert to the desired resolution of the digital signal (for example, 12 bits for the ADC 410) corresponding to the monitored analyte level associated with the sensor 101, the processor 204 may be configured to dynamically toggle or switch from using the voltage signal received from one of the two input terminals 411, 412, to using the voltage signal from the other one of the two input terminals 411, 412 to provide a dynamic range of tolerance level for the sensor sensitivities.


Accordingly, an apparatus in one embodiment includes a first amplifier having at least one input terminal and an output terminal, the at least one input terminal coupled to a signal source, the output terminal configured to provide a first output signal, a second amplifier having at least one input terminal and an output terminal, the at least one input terminal coupled to the output terminal of the first amplifier, the output terminal of the second amplifier configured to provide a second output signal, a processor operatively coupled to receive the first output signal and the second output signal, where the first output signal is a predetermined ratio of the second output signal, and further, where the first output signal and the second output signal are associated with a monitored analyte level of a user.


In one aspect, the first amplifier may include a transimpedance amplifier.


The monitored analyte level may include glucose level.


Also, the at least one input terminal of the first amplifier may include an inverting input terminal, and, also may include a reference signal source coupled to a noninverting input terminal of the first amplifier.


In a further aspect, the second amplifier may include a gain of approximately two.


In still another aspect, the first output signal may be associated with a signal level from the signal source.


The apparatus may also include an analog to digital converter coupled to the output terminals of the first and second amplifiers, where the analog to digital (A/D) converter may include a 12 bit A/D converter.


The apparatus in another embodiment may include a processor operatively coupled to the A/D converter for processing the one or more signals received at the one or more first amplifier output terminal and the second amplifier output terminal.


Moreover, the processor may be configured to compare the one or more signals received at the one or more first amplifier output terminal and the second amplifier output terminal to a predetermined threshold value, which, in one embodiment may include approximately 4,000 bits (or analog to digital converter (ADC) counts).


Still further, the processor may be configured to process a signal associated with one of the one or more signals received at the one or more first amplifier output terminal and the second amplifier output terminal when another signal associated with the other one of the one or more signals received at the one or more first amplifier output terminal and the second amplifier output terminal exceeds the predetermined threshold value.


A method in accordance with another embodiment includes receiving a first signal having a first signal resolution and associated with a monitored analyte level of a user, receiving a second signal having a second signal resolution and associated with the monitored analyte level of the user, comparing the received first signal to a predetermined threshold level, and processing one of the received first or second signals based on the comparing step.


When the received first signal does not exceed the predetermined threshold level, further including processing the first signal. On the other hand, when the received first signal exceeds the predetermined threshold level, further including processing the second signal.


A data processing device in accordance with still another embodiment includes a multi stage amplifier unit configured to receive a signal and to generate a plurality of amplifier unit output signals each corresponding to a monitored analyte level of a patient, an analog to digital (A/D) conversion unit operatively coupled to the multi-stage amplifier unit configured to digitally convert the plurality of amplifier unit output signals, and a processor unit operatively coupled to the A/D conversion unit, the processor unit configured to process one of the plurality of digitally converted amplifier unit output signals.


The device in another aspect may include a data communication unit operatively coupled to the processor unit, and configured to transmit the digitally converted and processed amplifier unit output signal.


The data communication unit may include an RF transmitter for wireless data transmission to a remote device such as, for example, a data receiver unit, data processing terminal, an infusion device or the like configured for RF communication.


Various other modifications and alterations in the structure and method of operation of this invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. It is intended that the following claims define the scope of the present invention and that structures and methods within the scope of these claims and their equivalents be covered thereby.

Claims
  • 1. A method of processing signals from an analyte sensor, comprising: coupling a first amplifier to a second amplifier and a signal source;determining that a first signal at an output terminal of the second amplifier exceeds a converter tolerance value; andprocessing a second signal at the output terminal of the second amplifier when the first signal at the output terminal of the second amplifier exceeds the converter tolerance value.
  • 2. The method of claim 1, wherein the first amplifier comprises a transimpedance amplifier.
  • 3. The method of claim 2, wherein the transimpedance amplifier is coupled to an analog to digital converter, and wherein the converter tolerance value corresponds to a tolerance level of the analog to digital converter.
  • 4. The method of claim 1, wherein the first amplifier has a higher resolution than the second amplifier.
  • 5. The method of claim 1, wherein the first signal and the second signal are from an in vivo analyte sensor.
  • 6. The method of claim 5, wherein the in vivo analyte sensor comprises a plurality of electrodes including a working electrode comprising an analyte-responsive enzyme bonded to a polymer disposed on the working electrode.
  • 7. The method of claim 6, wherein the analyte-responsive enzyme is chemically bonded to the polymer.
  • 8. The method of claim 6, wherein the working electrode further comprises a mediator.
  • 9. The method of claim 5, wherein the in vivo analyte sensor comprises a plurality of electrodes including a working electrode comprising a mediator bonded to a polymer disposed on the working electrode.
  • 10. The method of claim 9, wherein the mediator is chemically bonded to the polymer.
  • 11. An apparatus, comprising: a first amplifier operatively coupled to a signal source;a second amplifier operatively coupled to the first amplifier, the second amplifier comprising an output terminal; anda processing unit operatively coupled to one or more of the first amplifier and the second amplifier, the processing unit configured to: determine that a first signal at the output terminal of the second amplifier exceeds a converter tolerance value; andprocess a second signal at the output terminal of the second amplifier when the first signal at the output terminal of the second amplifier exceeds the converter tolerance value.
  • 12. The apparatus of claim 11, wherein the first amplifier comprises a transimpedance amplifier.
  • 13. The apparatus of claim 12, wherein the transimpedance amplifier is coupled to an analog to digital converter, and wherein the converter tolerance value corresponds to a tolerance level of the analog to digital converter.
  • 14. The apparatus of claim 11, wherein the first amplifier has a higher resolution than the second amplifier.
  • 15. The apparatus of claim 11, wherein the first signal and the second signal are sensor signals from an in vivo analyte sensor.
  • 16. The apparatus of claim 15, wherein the in vivo analyte sensor comprises a plurality of electrodes including a working electrode comprising an analyte-responsive enzyme bonded to a polymer disposed on the working electrode.
  • 17. The apparatus of claim 16, wherein the analyte-responsive enzyme is chemically bonded to the polymer.
  • 18. The apparatus of claim 16, wherein the working electrode further comprises a mediator.
  • 19. The apparatus of claim 15, wherein the in vivo analyte sensor comprises a plurality of electrodes including a working electrode comprising a mediator bonded to a polymer disposed on the working electrode.
  • 20. The apparatus of claim 19, wherein the mediator is chemically bonded to the polymer.
RELATED APPLICATIONS

The present application is a continuation of U.S. patent application Ser. No. 15/209,741 filed Jul. 13, 2016, now U.S. Pat. No. 9,743,866, which is a continuation of U.S. patent application Ser. No. 14/596,759 filed Jan. 14, 2015, now U.S. Pat. No. 9,402,584, which is a continuation of U.S. patent application Ser. No. 14/188,659 filed Feb. 24, 2014, now U.S. Pat. No. 8,937,540, which is a continuation of U.S. patent application Ser. No. 13/867,948 filed Apr. 22, 2013, now U.S. Pat. No. 8,698,615, which is a continuation of U.S. patent application Ser. No. 13/437,894 filed Apr. 2, 2012, now U.S. Pat. No. 8,427,298, which is a continuation of U.S. patent application Ser. No. 13/114,029 filed May 23, 2011, now U.S. Pat. No. 8,149,103, which is a continuation of U.S. patent application Ser. No. 12/849,004 filed Aug. 2, 2010, now U.S. Pat. No. 7,948,369, which is a continuation of U.S. patent application Ser. No. 12/102,836 filed Apr. 14, 2008, now U.S. Pat. No. 7,768,387, which claims priority under § 35 U.S.C. 119(e) to U.S. Provisional Application No. 60/911,866 filed Apr. 14, 2007, entitled “Method and Apparatus for Providing Dynamic Multi-Stage Signal Amplification in a Medical Device”, the disclosures of each of which are incorporated herein by reference for all purposes.

US Referenced Citations (791)
Number Name Date Kind
3260656 Ross, Jr. Jul 1966 A
3581062 Aston May 1971 A
3926760 Allen et al. Dec 1975 A
3949388 Fuller Apr 1976 A
4031449 Trombly Jun 1977 A
4036749 Anderson Jul 1977 A
4055175 Clemens et al. Oct 1977 A
4129128 McFarlane Dec 1978 A
4245634 Albisser et al. Jan 1981 A
4327725 Cortese et al. May 1982 A
4344438 Schultz Aug 1982 A
4349728 Phillips et al. Sep 1982 A
4425920 Bourland et al. Jan 1984 A
4445090 Melocik et al. Apr 1984 A
4464170 Clemens et al. Aug 1984 A
4478976 Goertz et al. Oct 1984 A
4494950 Fischell Jan 1985 A
4509531 Ward Apr 1985 A
4527240 Kvitash Jul 1985 A
4538616 Rogoff Sep 1985 A
4583035 Sloan Apr 1986 A
4619793 Lee Oct 1986 A
4671288 Gough Jun 1987 A
4703756 Gough et al. Nov 1987 A
4731726 Allen, III Mar 1988 A
4749985 Corsberg Jun 1988 A
4757022 Shults et al. Jul 1988 A
4777953 Ash et al. Oct 1988 A
4779618 Mund et al. Oct 1988 A
4847785 Stephens Jul 1989 A
4854322 Ash et al. Aug 1989 A
4890620 Gough Jan 1990 A
4925268 Iyer et al. May 1990 A
4953552 DeMarzo Sep 1990 A
4986271 Wilkins Jan 1991 A
4995402 Smith et al. Feb 1991 A
5000180 Kuypers et al. Mar 1991 A
5002054 Ash et al. Mar 1991 A
5019974 Beckers May 1991 A
5050612 Matsumura Sep 1991 A
5055171 Peck Oct 1991 A
5061941 Lizzi et al. Oct 1991 A
5068536 Rosenthal Nov 1991 A
5082550 Rishpon et al. Jan 1992 A
5106365 Hernandez Apr 1992 A
5112455 Cozzette et al. May 1992 A
5122925 Inpyn Jun 1992 A
5135004 Adams et al. Aug 1992 A
5165407 Wilson et al. Nov 1992 A
5246867 Lakowicz et al. Sep 1993 A
5262035 Gregg et al. Nov 1993 A
5262305 Heller et al. Nov 1993 A
5264104 Gregg et al. Nov 1993 A
5264105 Gregg et al. Nov 1993 A
5279294 Anderson et al. Jan 1994 A
5285792 Sjoquist et al. Feb 1994 A
5293877 O'Hara et al. Mar 1994 A
5299571 Mastrototaro Apr 1994 A
5320725 Gregg et al. Jun 1994 A
5322063 Allen et al. Jun 1994 A
5340722 Wolfbeis et al. Aug 1994 A
5342789 Chick et al. Aug 1994 A
5356786 Heller et al. Oct 1994 A
5360404 Novacek et al. Nov 1994 A
5371787 Hamilton Dec 1994 A
5372427 Padovani et al. Dec 1994 A
5379238 Stark Jan 1995 A
5390671 Lord et al. Feb 1995 A
5391250 Cheney, II et al. Feb 1995 A
5408999 Singh et al. Apr 1995 A
5411647 Johnson et al. May 1995 A
5425868 Pedersen Jun 1995 A
5429602 Hauser Jul 1995 A
5431160 Wilkins Jul 1995 A
5431921 Thombre Jul 1995 A
5438271 White et al. Aug 1995 A
5438983 Falcone Aug 1995 A
5462051 Oka et al. Oct 1995 A
5462645 Albery et al. Oct 1995 A
5497772 Schulman et al. Mar 1996 A
5507288 Bocker et al. Apr 1996 A
5509410 Hill et al. Apr 1996 A
5514718 Lewis et al. May 1996 A
5531878 Vadgama et al. Jul 1996 A
5558638 Evers et al. Sep 1996 A
5568806 Cheney, II et al. Oct 1996 A
5569186 Lord et al. Oct 1996 A
5582184 Erickson et al. Dec 1996 A
5586553 Halili et al. Dec 1996 A
5593852 Heller et al. Jan 1997 A
5609575 Larson et al. Mar 1997 A
5628310 Rao et al. May 1997 A
5628324 Sarbach May 1997 A
5653239 Pompei et al. Aug 1997 A
5665222 Heller et al. Sep 1997 A
5711001 Bussan et al. Jan 1998 A
5711861 Ward et al. Jan 1998 A
5726646 Bane et al. Mar 1998 A
5729225 Ledzius Mar 1998 A
5733313 Barreras, Sr. et al. Mar 1998 A
5769873 Zadeh Jun 1998 A
5772586 Heinonen et al. Jun 1998 A
5791344 Schulman et al. Aug 1998 A
5830129 Baer et al. Nov 1998 A
5830132 Robinson Nov 1998 A
5856758 Joffe et al. Jan 1999 A
5899855 Brown May 1999 A
5919141 Money et al. Jul 1999 A
5925021 Castellano et al. Jul 1999 A
5935224 Svancarek et al. Aug 1999 A
5942979 Luppino Aug 1999 A
5957854 Besson et al. Sep 1999 A
5964993 Blubaugh, Jr. et al. Oct 1999 A
5965380 Heller et al. Oct 1999 A
5971922 Arita et al. Oct 1999 A
5995860 Sun et al. Nov 1999 A
6001067 Shults et al. Dec 1999 A
6024699 Surwit et al. Feb 2000 A
6028413 Brockmann Feb 2000 A
6049727 Crothall Apr 2000 A
6055316 Perlman et al. Apr 2000 A
6066448 Wohlstadter et al. May 2000 A
6083710 Heller et al. Jul 2000 A
6084523 Gelnovatch et al. Jul 2000 A
6088608 Schulman et al. Jul 2000 A
6091976 Pfeiffer et al. Jul 2000 A
6093172 Funderburk et al. Jul 2000 A
6096364 Bok et al. Aug 2000 A
6103033 Say et al. Aug 2000 A
6117290 Say et al. Sep 2000 A
6119028 Schulman et al. Sep 2000 A
6120676 Heller et al. Sep 2000 A
6121009 Heller et al. Sep 2000 A
6121611 Lindsay et al. Sep 2000 A
6122351 Schlueter, Jr. et al. Sep 2000 A
6134461 Say et al. Oct 2000 A
6151517 Honigs et al. Nov 2000 A
6162611 Heller et al. Dec 2000 A
6175752 Say et al. Jan 2001 B1
6200265 Walsh et al. Mar 2001 B1
6212416 Ward et al. Apr 2001 B1
6218809 Downs et al. Apr 2001 B1
6219574 Cormier et al. Apr 2001 B1
6233471 Berner et al. May 2001 B1
6248067 Causey, III et al. Jun 2001 B1
6270455 Brown Aug 2001 B1
6275717 Gross et al. Aug 2001 B1
6284478 Heller et al. Sep 2001 B1
6293925 Safabash et al. Sep 2001 B1
6295506 Heinonen et al. Sep 2001 B1
6299347 Pompei Oct 2001 B1
6306104 Cunningham et al. Oct 2001 B1
6309884 Cooper et al. Oct 2001 B1
6314317 Willis Nov 2001 B1
6329161 Heller et al. Dec 2001 B1
6359270 Bridson Mar 2002 B1
6359594 Junod Mar 2002 B1
6360888 McIvor et al. Mar 2002 B1
6366794 Moussy et al. Apr 2002 B1
6377828 Chaiken et al. Apr 2002 B1
6379301 Worthington et al. Apr 2002 B1
6385473 Haines et al. May 2002 B1
6424847 Mastrototaro et al. Jul 2002 B1
6427088 Bowman, IV et al. Jul 2002 B1
6440068 Brown et al. Aug 2002 B1
6471689 Joseph et al. Oct 2002 B1
6478736 Mault Nov 2002 B1
6480744 Ferek-Petric Nov 2002 B2
6484046 Say et al. Nov 2002 B1
6493069 Nagashimada et al. Dec 2002 B1
6514718 Heller et al. Feb 2003 B2
6533733 Ericson et al. Mar 2003 B1
6544212 Galley et al. Apr 2003 B2
6546268 Ishikawa et al. Apr 2003 B1
6551494 Heller et al. Apr 2003 B1
6558321 Burd et al. May 2003 B1
6558351 Steil et al. May 2003 B1
6560471 Heller et al. May 2003 B1
6561978 Conn et al. May 2003 B1
6562001 Lebel et al. May 2003 B2
6564105 Starkweather et al. May 2003 B2
6565509 Say et al. May 2003 B1
6571128 Lebel et al. May 2003 B2
6572545 Knobbe et al. Jun 2003 B2
6576101 Heller et al. Jun 2003 B1
6577899 Lebel et al. Jun 2003 B2
6579690 Bonnecaze et al. Jun 2003 B1
6580364 Munch et al. Jun 2003 B1
6585644 Lebel et al. Jul 2003 B2
6591125 Buse et al. Jul 2003 B1
6595919 Berner et al. Jul 2003 B2
6599243 Woltermann et al. Jul 2003 B2
6605200 Mao et al. Aug 2003 B1
6605201 Mao et al. Aug 2003 B1
6607509 Bobroff et al. Aug 2003 B2
6610012 Mault Aug 2003 B2
6633772 Ford et al. Oct 2003 B2
6635014 Starkweather et al. Oct 2003 B2
6645368 Beaty et al. Nov 2003 B1
6648821 Lebel et al. Nov 2003 B2
6654625 Say et al. Nov 2003 B1
6656114 Poulson et al. Dec 2003 B1
6658396 Tang et al. Dec 2003 B1
6659948 Lebel et al. Dec 2003 B2
6668196 Villegas et al. Dec 2003 B1
6687546 Lebel et al. Feb 2004 B2
6689056 Kilcoyne et al. Feb 2004 B1
6692446 Hoek Feb 2004 B2
6694191 Starkweather et al. Feb 2004 B2
6695860 Ward et al. Feb 2004 B1
6698269 Baber et al. Mar 2004 B2
6702857 Brauker et al. Mar 2004 B2
6730025 Platt May 2004 B1
6733446 Lebel et al. May 2004 B2
6740075 Lebel et al. May 2004 B2
6741877 Shults et al. May 2004 B1
6746582 Heller et al. Jun 2004 B2
6758810 Lebel et al. Jul 2004 B2
6770030 Schaupp et al. Aug 2004 B1
6790178 Mault et al. Sep 2004 B1
6809653 Mann et al. Oct 2004 B1
6810290 Lebel et al. Oct 2004 B2
6811533 Lebel et al. Nov 2004 B2
6811534 Bowman, IV et al. Nov 2004 B2
6813519 Lebel et al. Nov 2004 B2
6862465 Shults et al. Mar 2005 B2
6873268 Lebel et al. Mar 2005 B2
6881551 Heller et al. Apr 2005 B2
6892085 McIvor et al. May 2005 B2
6893396 Schulze et al. May 2005 B2
6895263 Shin et al. May 2005 B2
6895265 Silver May 2005 B2
6926670 Rich et al. Aug 2005 B2
6931327 Goode, Jr. et al. Aug 2005 B2
6932894 Mao et al. Aug 2005 B2
6936006 Sabra Aug 2005 B2
6950708 Bowman, IV et al. Sep 2005 B2
6958705 Lebel et al. Oct 2005 B2
6968294 Gutta et al. Nov 2005 B2
6971274 Olin Dec 2005 B2
6974437 Lebel et al. Dec 2005 B2
6983176 Gardner et al. Jan 2006 B2
6987474 Freeman et al. Jan 2006 B2
6990317 Arnold Jan 2006 B2
6990366 Say et al. Jan 2006 B2
6997907 Safabash et al. Feb 2006 B2
6998247 Monfre et al. Feb 2006 B2
7003336 Holker et al. Feb 2006 B2
7003340 Say et al. Feb 2006 B2
7003341 Say et al. Feb 2006 B2
7022072 Fox et al. Apr 2006 B2
7024245 Lebel et al. Apr 2006 B2
7027621 Prokoski Apr 2006 B1
7027931 Jones et al. Apr 2006 B1
7029444 Shin et al. Apr 2006 B2
7041068 Freeman et al. May 2006 B2
7052483 Wojcik May 2006 B2
7056302 Douglas Jun 2006 B2
7068227 Ying Jun 2006 B2
7074307 Simpson et al. Jul 2006 B2
7081195 Simpson et al. Jul 2006 B2
7098803 Mann et al. Aug 2006 B2
7108778 Simpson et al. Sep 2006 B2
7110803 Shults et al. Sep 2006 B2
7113821 Sun et al. Sep 2006 B1
7134999 Brauker et al. Nov 2006 B2
7136689 Shults et al. Nov 2006 B2
7167818 Brown Jan 2007 B2
7171274 Starkweather et al. Jan 2007 B2
7174199 Berner et al. Feb 2007 B2
7181505 Haller et al. Feb 2007 B2
7190988 Say et al. Mar 2007 B2
7192450 Brauker et al. Mar 2007 B2
7198606 Boecker et al. Apr 2007 B2
7222054 Geva May 2007 B2
7226978 Tapsak et al. Jun 2007 B2
7258665 Kohls et al. Aug 2007 B2
7267665 Steil et al. Sep 2007 B2
7276029 Goode, Jr. et al. Oct 2007 B2
7286894 Grant et al. Oct 2007 B1
7299082 Feldman et al. Nov 2007 B2
7310544 Brister et al. Dec 2007 B2
7335294 Heller et al. Feb 2008 B2
7354420 Steil et al. Apr 2008 B2
7364592 Carr-Brendel et al. Apr 2008 B2
7366556 Brister et al. Apr 2008 B2
7379765 Petisce et al. May 2008 B2
7402153 Steil et al. Jul 2008 B2
7424318 Brister et al. Sep 2008 B2
7460898 Brister et al. Dec 2008 B2
7467003 Brister et al. Dec 2008 B2
7471972 Rhodes et al. Dec 2008 B2
7494465 Brister et al. Feb 2009 B2
7497827 Brister et al. Mar 2009 B2
7506046 Rhodes Mar 2009 B2
7519408 Rasdal et al. Apr 2009 B2
7547281 Hayes et al. Jun 2009 B2
7569030 Lebel et al. Aug 2009 B2
7583990 Goode, Jr. et al. Sep 2009 B2
7591801 Brauker et al. Sep 2009 B2
7599726 Goode, Jr. et al. Oct 2009 B2
7613491 Boock et al. Nov 2009 B2
7615007 Shults et al. Nov 2009 B2
7618369 Hayter et al. Nov 2009 B2
7632228 Brauker et al. Dec 2009 B2
7653425 Hayter et al. Jan 2010 B2
7699775 Desai et al. Apr 2010 B2
7766829 Sloan et al. Aug 2010 B2
7768387 Fennell et al. Aug 2010 B2
7775444 DeRocco et al. Aug 2010 B2
7804197 Iisaka et al. Sep 2010 B2
7811231 Jin et al. Oct 2010 B2
7826382 Sicurello et al. Nov 2010 B2
7833151 Khait et al. Nov 2010 B2
7889069 Fifolt et al. Feb 2011 B2
7948369 Fennell et al. May 2011 B2
7978063 Baldus et al. Jul 2011 B2
8000918 Fjield et al. Aug 2011 B2
8010174 Goode et al. Aug 2011 B2
8010256 Oowada Aug 2011 B2
8123686 Fennell et al. Feb 2012 B2
8149103 Fennell et al. Apr 2012 B2
8233456 Kopikare et al. Jul 2012 B1
8260393 Kamath et al. Sep 2012 B2
8282549 Brauker et al. Oct 2012 B2
8417312 Kamath et al. Apr 2013 B2
8427298 Fennell et al. Apr 2013 B2
8478389 Brockway et al. Jul 2013 B1
8560037 Goode, Jr. et al. Oct 2013 B2
8622903 Jin et al. Jan 2014 B2
8638411 Park et al. Jan 2014 B2
8698615 Fennell et al. Apr 2014 B2
8849459 Ramey et al. Sep 2014 B2
8914090 Jain et al. Dec 2014 B2
8937540 Fennell Jan 2015 B2
9402584 Fennell Aug 2016 B2
9743866 Fennell Aug 2017 B2
9801545 Fennell et al. Oct 2017 B2
20010011795 Ohtsuka et al. Aug 2001 A1
20020019022 Dunn et al. Feb 2002 A1
20020023852 McIvor et al. Feb 2002 A1
20020026111 Ackerman Feb 2002 A1
20020042090 Heller et al. Apr 2002 A1
20020045808 Ford et al. Apr 2002 A1
20020046300 Hanko et al. Apr 2002 A1
20020065454 Lebel et al. May 2002 A1
20020085719 Crosbie Jul 2002 A1
20020099854 Jorgensen Jul 2002 A1
20020103499 Perez et al. Aug 2002 A1
20020106709 Potts et al. Aug 2002 A1
20020109621 Khair et al. Aug 2002 A1
20020117639 Paolini et al. Aug 2002 A1
20020128594 Das et al. Sep 2002 A1
20020161288 Shin et al. Oct 2002 A1
20020169635 Shillingburg Nov 2002 A1
20020173830 Starkweather et al. Nov 2002 A1
20020185130 Wright et al. Dec 2002 A1
20020188748 Blackwell et al. Dec 2002 A1
20030004403 Drinan et al. Jan 2003 A1
20030009203 Lebel et al. Jan 2003 A1
20030023317 Brauker et al. Jan 2003 A1
20030032874 Rhodes et al. Feb 2003 A1
20030035371 Reed et al. Feb 2003 A1
20030042137 Mao et al. Mar 2003 A1
20030060689 Kohls et al. Mar 2003 A1
20030060692 Ruchti et al. Mar 2003 A1
20030060753 Starkweather et al. Mar 2003 A1
20030065308 Lebel et al. Apr 2003 A1
20030100821 Heller et al. May 2003 A1
20030119457 Standke Jun 2003 A1
20030125612 Fox et al. Jul 2003 A1
20030130616 Steil et al. Jul 2003 A1
20030134347 Heller et al. Jul 2003 A1
20030144581 Conn et al. Jul 2003 A1
20030168338 Gao et al. Sep 2003 A1
20030175992 Toranto et al. Sep 2003 A1
20030176933 Lebel et al. Sep 2003 A1
20030179705 Kojima Sep 2003 A1
20030187338 Say et al. Oct 2003 A1
20030199790 Boecker et al. Oct 2003 A1
20030208113 Mault et al. Nov 2003 A1
20030212317 Kovatchev et al. Nov 2003 A1
20030212379 Bylund et al. Nov 2003 A1
20030216630 Jersey-Willuhn et al. Nov 2003 A1
20030217966 Tapsak et al. Nov 2003 A1
20040010207 Flaherty et al. Jan 2004 A1
20040011671 Shults et al. Jan 2004 A1
20040030581 Levin et al. Feb 2004 A1
20040034289 Teller et al. Feb 2004 A1
20040039255 Simonsen et al. Feb 2004 A1
20040039298 Abreu et al. Feb 2004 A1
20040040840 Mao et al. Mar 2004 A1
20040045879 Shults et al. Mar 2004 A1
20040063435 Sakamoto et al. Apr 2004 A1
20040064068 DeNuzzio et al. Apr 2004 A1
20040106858 Say et al. Jun 2004 A1
20040106859 Say et al. Jun 2004 A1
20040116786 Iijima et al. Jun 2004 A1
20040122353 Shahmirian et al. Jun 2004 A1
20040128161 Mazar et al. Jul 2004 A1
20040133164 Funderburk et al. Jul 2004 A1
20040133390 Osorio et al. Jul 2004 A1
20040136361 Holloway et al. Jul 2004 A1
20040136377 Miyazaki et al. Jul 2004 A1
20040138588 Saikley et al. Jul 2004 A1
20040146909 Duong et al. Jul 2004 A1
20040147872 Thompson Jul 2004 A1
20040152622 Keith et al. Aug 2004 A1
20040167801 Say et al. Aug 2004 A1
20040171921 Say et al. Sep 2004 A1
20040176672 Silver et al. Sep 2004 A1
20040186362 Brauker et al. Sep 2004 A1
20040186365 Jin et al. Sep 2004 A1
20040193020 Chiba et al. Sep 2004 A1
20040193025 Steil et al. Sep 2004 A1
20040193090 Lebel et al. Sep 2004 A1
20040197846 Hockersmith et al. Oct 2004 A1
20040199056 Husemann et al. Oct 2004 A1
20040199059 Brauker et al. Oct 2004 A1
20040204055 Nousiainen Oct 2004 A1
20040204687 Mogensen et al. Oct 2004 A1
20040204868 Maynard et al. Oct 2004 A1
20040206916 Colvin, Jr. et al. Oct 2004 A1
20040212536 Mori et al. Oct 2004 A1
20040225199 Evanyk et al. Nov 2004 A1
20040225338 Lebel et al. Nov 2004 A1
20040236200 Say et al. Nov 2004 A1
20040254433 Bandis et al. Dec 2004 A1
20040260478 Schwamm Dec 2004 A1
20040267300 Mace Dec 2004 A1
20050001024 Kusaka et al. Jan 2005 A1
20050004439 Shin et al. Jan 2005 A1
20050004494 Perez et al. Jan 2005 A1
20050010269 Lebel et al. Jan 2005 A1
20050017864 Tsoukalis Jan 2005 A1
20050027177 Shin et al. Feb 2005 A1
20050031689 Shults et al. Feb 2005 A1
20050038332 Saidara et al. Feb 2005 A1
20050043598 Goode, Jr. et al. Feb 2005 A1
20050049179 Davidson et al. Mar 2005 A1
20050059372 Arayashiki et al. Mar 2005 A1
20050070777 Cho et al. Mar 2005 A1
20050090607 Tapsak et al. Apr 2005 A1
20050096511 Fox et al. May 2005 A1
20050096512 Fox et al. May 2005 A1
20050096516 Soykan et al. May 2005 A1
20050112169 Brauker et al. May 2005 A1
20050113648 Yang et al. May 2005 A1
20050113653 Fox et al. May 2005 A1
20050114068 Chey et al. May 2005 A1
20050116683 Cheng et al. Jun 2005 A1
20050121322 Say et al. Jun 2005 A1
20050131346 Douglas Jun 2005 A1
20050137530 Campbell et al. Jun 2005 A1
20050143635 Kamath et al. Jun 2005 A1
20050176136 Burd et al. Aug 2005 A1
20050177398 Watanabe et al. Aug 2005 A1
20050182306 Sloan Aug 2005 A1
20050182358 Veit et al. Aug 2005 A1
20050187720 Goode, Jr. et al. Aug 2005 A1
20050192494 Ginsberg Sep 2005 A1
20050192557 Brauker et al. Sep 2005 A1
20050195930 Spital et al. Sep 2005 A1
20050199494 Say et al. Sep 2005 A1
20050203360 Brauker et al. Sep 2005 A1
20050221504 Petruno et al. Oct 2005 A1
20050236361 Ufer et al. Oct 2005 A1
20050239154 Feldman et al. Oct 2005 A1
20050241957 Mao et al. Nov 2005 A1
20050242479 Petisce et al. Nov 2005 A1
20050245795 Goode, Jr. et al. Nov 2005 A1
20050245799 Brauker et al. Nov 2005 A1
20050245839 Stivoric et al. Nov 2005 A1
20050245904 Estes et al. Nov 2005 A1
20050259514 Iseli et al. Nov 2005 A1
20050277912 John Dec 2005 A1
20050287620 Heller et al. Dec 2005 A1
20060001538 Kraft et al. Jan 2006 A1
20060004270 Bedard et al. Jan 2006 A1
20060015020 Neale et al. Jan 2006 A1
20060015024 Brister et al. Jan 2006 A1
20060016700 Brister et al. Jan 2006 A1
20060019327 Brister et al. Jan 2006 A1
20060020186 Brister et al. Jan 2006 A1
20060020187 Brister et al. Jan 2006 A1
20060020188 Kamath et al. Jan 2006 A1
20060020189 Brister et al. Jan 2006 A1
20060020190 Kamath et al. Jan 2006 A1
20060020191 Brister et al. Jan 2006 A1
20060020192 Brister et al. Jan 2006 A1
20060020300 Nghiem et al. Jan 2006 A1
20060029177 Cranford, Jr. et al. Feb 2006 A1
20060031094 Cohen et al. Feb 2006 A1
20060036139 Brister et al. Feb 2006 A1
20060036140 Brister et al. Feb 2006 A1
20060036141 Kamath et al. Feb 2006 A1
20060036142 Brister et al. Feb 2006 A1
20060036143 Brister et al. Feb 2006 A1
20060036144 Brister et al. Feb 2006 A1
20060036145 Brister et al. Feb 2006 A1
20060058588 Zdeblick Mar 2006 A1
20060154642 Scannell Jul 2006 A1
20060155180 Brister et al. Jul 2006 A1
20060166629 Reggiardo Jul 2006 A1
20060173260 Gaoni et al. Aug 2006 A1
20060173406 Hayes et al. Aug 2006 A1
20060173444 Choy et al. Aug 2006 A1
20060183984 Dobbles et al. Aug 2006 A1
20060183985 Brister et al. Aug 2006 A1
20060189863 Peyser et al. Aug 2006 A1
20060193375 Lee et al. Aug 2006 A1
20060198426 Partyka Sep 2006 A1
20060222566 Brauker et al. Oct 2006 A1
20060224109 Steil et al. Oct 2006 A1
20060229512 Petisce et al. Oct 2006 A1
20060247508 Fennell Nov 2006 A1
20060253296 Liisberg et al. Nov 2006 A1
20060264785 Dring et al. Nov 2006 A1
20060264888 Moberg et al. Nov 2006 A1
20060270922 Brauker et al. Nov 2006 A1
20060272652 Stocker et al. Dec 2006 A1
20060276714 Holt et al. Dec 2006 A1
20060293607 Alt et al. Dec 2006 A1
20070007133 Mang et al. Jan 2007 A1
20070016381 Kamath et al. Jan 2007 A1
20070017983 Frank et al. Jan 2007 A1
20070026440 Broderick et al. Feb 2007 A1
20070027381 Stafford Feb 2007 A1
20070027507 Burdett et al. Feb 2007 A1
20070032706 Kamath et al. Feb 2007 A1
20070033074 Nitzan et al. Feb 2007 A1
20070038044 Dobbles et al. Feb 2007 A1
20070053341 Lizzi Mar 2007 A1
20070060814 Stafford Mar 2007 A1
20070060869 Tolle et al. Mar 2007 A1
20070066873 Kamath et al. Mar 2007 A1
20070066877 Arnold et al. Mar 2007 A1
20070071681 Gadkar et al. Mar 2007 A1
20070073129 Shah et al. Mar 2007 A1
20070078320 Stafford Apr 2007 A1
20070078321 Mazza et al. Apr 2007 A1
20070078322 Stafford Apr 2007 A1
20070078323 Reggiardo et al. Apr 2007 A1
20070093786 Goldsmith et al. Apr 2007 A1
20070100222 Mastrototaro et al. May 2007 A1
20070106133 Satchwell et al. May 2007 A1
20070106135 Sloan et al. May 2007 A1
20070118030 Bruce et al. May 2007 A1
20070124002 Estes et al. May 2007 A1
20070135697 Reggiardo Jun 2007 A1
20070149875 Ouyang et al. Jun 2007 A1
20070153705 Rosar et al. Jul 2007 A1
20070156094 Safabash et al. Jul 2007 A1
20070163880 Woo et al. Jul 2007 A1
20070168224 Letzt et al. Jul 2007 A1
20070170893 Kao et al. Jul 2007 A1
20070173706 Neinast et al. Jul 2007 A1
20070173712 Shah et al. Jul 2007 A1
20070173761 Kanderian et al. Jul 2007 A1
20070179349 Hoyme et al. Aug 2007 A1
20070179352 Randlov et al. Aug 2007 A1
20070191701 Feldman et al. Aug 2007 A1
20070191702 Yodfat et al. Aug 2007 A1
20070203407 Hoss et al. Aug 2007 A1
20070203966 Brauker et al. Aug 2007 A1
20070208245 Brauker et al. Sep 2007 A1
20070219496 Kamen et al. Sep 2007 A1
20070222609 Duron et al. Sep 2007 A1
20070235331 Simpson et al. Oct 2007 A1
20070249922 Peyser et al. Oct 2007 A1
20070255321 Gerber et al. Nov 2007 A1
20070255348 Holtzclaw Nov 2007 A1
20070271285 Eichorn et al. Nov 2007 A1
20080009692 Stafford Jan 2008 A1
20080012701 Kass et al. Jan 2008 A1
20080017522 Heller et al. Jan 2008 A1
20080021666 Goode, Jr. et al. Jan 2008 A1
20080021972 Huelskamp et al. Jan 2008 A1
20080027586 Hern et al. Jan 2008 A1
20080029391 Mao et al. Feb 2008 A1
20080033254 Kamath et al. Feb 2008 A1
20080039702 Hayter et al. Feb 2008 A1
20080045824 Tapsak et al. Feb 2008 A1
20080057484 Miyata et al. Mar 2008 A1
20080058625 McGarraugh et al. Mar 2008 A1
20080058626 Miyata et al. Mar 2008 A1
20080058678 Miyata et al. Mar 2008 A1
20080060955 Goodnow Mar 2008 A1
20080062055 Cunningham et al. Mar 2008 A1
20080064937 McGarraugh et al. Mar 2008 A1
20080067627 Boeck et al. Mar 2008 A1
20080071156 Brister et al. Mar 2008 A1
20080071157 McGarraugh et al. Mar 2008 A1
20080071158 McGarraugh et al. Mar 2008 A1
20080081977 Hayter et al. Apr 2008 A1
20080083617 Simpson et al. Apr 2008 A1
20080086042 Brister et al. Apr 2008 A1
20080086044 Brister et al. Apr 2008 A1
20080086273 Shults et al. Apr 2008 A1
20080092638 Brenneman et al. Apr 2008 A1
20080097289 Steil et al. Apr 2008 A1
20080108942 Brister et al. May 2008 A1
20080154513 Kovatchev et al. Jun 2008 A1
20080161666 Feldman et al. Jul 2008 A1
20080167543 Say et al. Jul 2008 A1
20080172205 Breton et al. Jul 2008 A1
20080179187 Ouyang et al. Jul 2008 A1
20080183060 Steil et al. Jul 2008 A1
20080183061 Goode et al. Jul 2008 A1
20080183399 Goode et al. Jul 2008 A1
20080188731 Brister et al. Aug 2008 A1
20080188796 Steil et al. Aug 2008 A1
20080189051 Goode et al. Aug 2008 A1
20080194934 Ray et al. Aug 2008 A1
20080194935 Brister et al. Aug 2008 A1
20080194936 Goode et al. Aug 2008 A1
20080194937 Goode et al. Aug 2008 A1
20080194938 Brister et al. Aug 2008 A1
20080195232 Carr-Brendel et al. Aug 2008 A1
20080195967 Goode et al. Aug 2008 A1
20080197024 Simpson et al. Aug 2008 A1
20080200788 Brister et al. Aug 2008 A1
20080200789 Brister et al. Aug 2008 A1
20080200791 Simpson et al. Aug 2008 A1
20080208025 Shults et al. Aug 2008 A1
20080208113 Damiano et al. Aug 2008 A1
20080212600 Yoo Sep 2008 A1
20080214900 Fennell et al. Sep 2008 A1
20080214915 Brister et al. Sep 2008 A1
20080214918 Brister et al. Sep 2008 A1
20080228051 Shults et al. Sep 2008 A1
20080228054 Shults et al. Sep 2008 A1
20080234943 Ray et al. Sep 2008 A1
20080242961 Brister et al. Oct 2008 A1
20080254544 Modzelewski et al. Oct 2008 A1
20080255434 Hayter et al. Oct 2008 A1
20080255437 Hayter Oct 2008 A1
20080255808 Hayter Oct 2008 A1
20080256048 Hayter Oct 2008 A1
20080262469 Brister et al. Oct 2008 A1
20080267823 Wang et al. Oct 2008 A1
20080275313 Brister et al. Nov 2008 A1
20080287761 Hayter Nov 2008 A1
20080287762 Hayter Nov 2008 A1
20080287763 Hayter Nov 2008 A1
20080287764 Rasdal et al. Nov 2008 A1
20080287765 Rasdal et al. Nov 2008 A1
20080287766 Rasdal et al. Nov 2008 A1
20080288180 Hayter Nov 2008 A1
20080288204 Hayter et al. Nov 2008 A1
20080294024 Cosentino et al. Nov 2008 A1
20080296155 Shults et al. Dec 2008 A1
20080301436 Yao et al. Dec 2008 A1
20080306368 Goode et al. Dec 2008 A1
20080306434 Dobbles et al. Dec 2008 A1
20080306435 Kamath et al. Dec 2008 A1
20080306444 Brister et al. Dec 2008 A1
20080312841 Hayter Dec 2008 A1
20080312842 Hayter Dec 2008 A1
20080312844 Hayter et al. Dec 2008 A1
20080312845 Hayter et al. Dec 2008 A1
20080319295 Bernstein et al. Dec 2008 A1
20080319296 Bernstein et al. Dec 2008 A1
20080320587 Vauclair et al. Dec 2008 A1
20090005665 Hayter et al. Jan 2009 A1
20090006034 Hayter et al. Jan 2009 A1
20090012379 Goode et al. Jan 2009 A1
20090018424 Kamath et al. Jan 2009 A1
20090030294 Petisce et al. Jan 2009 A1
20090033482 Hayter et al. Feb 2009 A1
20090036747 Hayter et al. Feb 2009 A1
20090036758 Brauker et al. Feb 2009 A1
20090036760 Hayter Feb 2009 A1
20090036763 Brauker et al. Feb 2009 A1
20090040022 Finkenzeller Feb 2009 A1
20090043181 Brauker et al. Feb 2009 A1
20090043182 Brauker et al. Feb 2009 A1
20090043525 Brauker et al. Feb 2009 A1
20090043541 Brauker et al. Feb 2009 A1
20090043542 Brauker et al. Feb 2009 A1
20090045055 Rhodes et al. Feb 2009 A1
20090048503 Dalal et al. Feb 2009 A1
20090054747 Fennell Feb 2009 A1
20090055149 Hayter et al. Feb 2009 A1
20090062633 Brauker et al. Mar 2009 A1
20090062635 Brauker et al. Mar 2009 A1
20090062767 VanAntwerp et al. Mar 2009 A1
20090063187 Johnson et al. Mar 2009 A1
20090063402 Hayter Mar 2009 A1
20090076356 Simpson et al. Mar 2009 A1
20090076359 Peyser et al. Mar 2009 A1
20090076360 Brister et al. Mar 2009 A1
20090076361 Kamath et al. Mar 2009 A1
20090085873 Betts et al. Apr 2009 A1
20090093687 Telfort et al. Apr 2009 A1
20090094680 Gupta et al. Apr 2009 A1
20090099436 Brister et al. Apr 2009 A1
20090105570 Sloan et al. Apr 2009 A1
20090105571 Fennell et al. Apr 2009 A1
20090105636 Hayter et al. Apr 2009 A1
20090124877 Goode et al. May 2009 A1
20090124878 Goode et al. May 2009 A1
20090124879 Brister et al. May 2009 A1
20090124964 Leach et al. May 2009 A1
20090131768 Simpson et al. May 2009 A1
20090131769 Leach et al. May 2009 A1
20090131776 Simpson et al. May 2009 A1
20090131777 Simpson et al. May 2009 A1
20090137886 Shariati et al. May 2009 A1
20090137887 Shariati et al. May 2009 A1
20090143659 Li et al. Jun 2009 A1
20090143660 Brister et al. Jun 2009 A1
20090146826 Gofman et al. Jun 2009 A1
20090156919 Brister et al. Jun 2009 A1
20090156924 Shariati et al. Jun 2009 A1
20090163790 Brister et al. Jun 2009 A1
20090163791 Brister et al. Jun 2009 A1
20090164190 Hayter Jun 2009 A1
20090164239 Hayter et al. Jun 2009 A1
20090164251 Hayter Jun 2009 A1
20090178459 Li et al. Jul 2009 A1
20090182217 Li et al. Jul 2009 A1
20090192366 Mensinger et al. Jul 2009 A1
20090192380 Shariati et al. Jul 2009 A1
20090192722 Shariati et al. Jul 2009 A1
20090192724 Brauker et al. Jul 2009 A1
20090192745 Kamath et al. Jul 2009 A1
20090192751 Kamath et al. Jul 2009 A1
20090198118 Hayter et al. Aug 2009 A1
20090203981 Brauker et al. Aug 2009 A1
20090204340 Feldman et al. Aug 2009 A1
20090204341 Brauker et al. Aug 2009 A1
20090216103 Brister et al. Aug 2009 A1
20090237216 Twitchell, Jr. Sep 2009 A1
20090240120 Mensinger et al. Sep 2009 A1
20090240128 Mensinger et al. Sep 2009 A1
20090240193 Mensinger et al. Sep 2009 A1
20090242399 Kamath et al. Oct 2009 A1
20090242425 Kamath et al. Oct 2009 A1
20090247855 Boock et al. Oct 2009 A1
20090247856 Boock et al. Oct 2009 A1
20090287073 Boock et al. Nov 2009 A1
20090287074 Shults et al. Nov 2009 A1
20090296742 Sicurello et al. Dec 2009 A1
20090299155 Yang et al. Dec 2009 A1
20090299156 Simpson et al. Dec 2009 A1
20090299162 Brauker et al. Dec 2009 A1
20090299276 Brauker et al. Dec 2009 A1
20100010329 Taub et al. Jan 2010 A1
20100025238 Gottlieb et al. Feb 2010 A1
20100057040 Hayter Mar 2010 A1
20100057041 Hayter Mar 2010 A1
20100057042 Hayter Mar 2010 A1
20100057044 Hayter Mar 2010 A1
20100057057 Hayter et al. Mar 2010 A1
20100105999 Dixon et al. Apr 2010 A1
20100110931 Shim et al. May 2010 A1
20100119881 Patel et al. May 2010 A1
20100152554 Steine et al. Jun 2010 A1
20100160759 Celentano et al. Jun 2010 A1
20100168538 Keenan et al. Jul 2010 A1
20100168545 Kamath et al. Jul 2010 A1
20100174266 Estes Jul 2010 A1
20100185071 Simpson et al. Jul 2010 A1
20100185175 Kamen et al. Jul 2010 A1
20100191085 Budiman Jul 2010 A1
20100198142 Sloan et al. Aug 2010 A1
20100213080 Celentano et al. Aug 2010 A1
20100235439 Goodnow et al. Sep 2010 A1
20100267161 Wu et al. Oct 2010 A1
20100313105 Nekoomaram et al. Dec 2010 A1
20100324403 Brister et al. Dec 2010 A1
20100331646 Hoss et al. Dec 2010 A1
20100332142 Shadforth et al. Dec 2010 A1
20110031986 Bhat et al. Feb 2011 A1
20110074349 Ghovanloo Mar 2011 A1
20110125040 Crawford et al. May 2011 A1
20110148905 Simmons et al. Jun 2011 A1
20110184268 Taub Jul 2011 A1
20110191059 Farrell et al. Aug 2011 A1
20110230741 Liang et al. Sep 2011 A1
20110257895 Brauker et al. Oct 2011 A1
20110270112 Manera et al. Nov 2011 A1
20110287528 Fern et al. Nov 2011 A1
20120108931 Taub et al. May 2012 A1
20120148054 Rank et al. Jun 2012 A1
20120190989 Kaiser et al. Jul 2012 A1
20120215092 Harris, III et al. Aug 2012 A1
20130035575 Mayou et al. Feb 2013 A1
20130235166 Jones et al. Sep 2013 A1
20150335245 Fennell et al. Nov 2015 A1
Foreign Referenced Citations (29)
Number Date Country
0098592 Jan 1984 EP
0127958 Dec 1984 EP
0320109 Jun 1989 EP
0353328 Feb 1990 EP
0390390 Oct 1990 EP
0396788 Nov 1990 EP
0286118 Jan 1995 EP
1048264 Nov 2000 EP
WO-1996025089 Aug 1996 WO
WO-1996035370 Nov 1996 WO
WO-1998035053 Aug 1998 WO
WO-1999056613 Nov 1999 WO
WO-2000049940 Aug 2000 WO
WO-2000059370 Oct 2000 WO
WO-2000060350 Oct 2000 WO
WO-2000078992 Dec 2000 WO
WO-2001052935 Jul 2001 WO
WO-2001054753 Aug 2001 WO
WO-2002016905 Feb 2002 WO
WO-2002058537 Aug 2002 WO
WO-2003076893 Sep 2003 WO
WO-2003082091 Oct 2003 WO
WO-2003085372 Oct 2003 WO
WO-2004061420 Jul 2004 WO
WO-2005010756 Feb 2005 WO
WO-2005041766 May 2005 WO
WO-2005089103 Sep 2005 WO
WO-2005117269 Dec 2005 WO
WO-2006024671 Mar 2006 WO
Non-Patent Literature Citations (64)
Entry
Armour, J. C., et al., “Application of Chronic Intravascular Blood Glucose Sensor in Dogs”, Diabetes, vol. 39, 1990, pp. 1519-1526.
Bennion, N., et al., “Alternate Site Glucose Testing: A Crossover Design”, Diabetes Technology & Therapeutics, vol. 4, No. 1, 2002, pp. 25-33.
Blank, T. B., et al., “Clinical Results From a Non-Invasive Blood Glucose Monitor”, Optical Diagnostics and Sensing of Biological Fluids and Glucose and Cholesterol Monitoring II, Proceedings of SPIE, vol. 4624, 2002, pp. 1-10.
Brooks, S. L., et al., “Development of an On-Line Glucose Sensor for Fermentation Monitoring”, Biosensors, vol. 3, 1987/1988, pp. 45-56.
Cass, A. E., et al., “Ferrocene-Medicated Enzyme Electrode for Amperometric Determination of Glucose” Analytical Chemistry, vol. 56, No. 4, 1984, 667-671.
Csoregi, E., et al., “Design and Optimization of a Selective Subcutaneously Implantable Glucose Electrode Based on ‘Wired’ Glucose Oxidase”, Analytical Chemistry, vol. 67, No. 7, 1995, pp. 1240-1244.
Feldman, B., et al., “A Continuous Glucose Sensor Based on Wired Enzyme™ Technology—Results from a 3-Day Trial in Patients with Type 1 Diabetes”, Diabetes Technology & Therapeutics, vol. 5, No. 5, 2003, pp. 769-779.
Feldman, B., et al., “Correlation of Glucose Concentrations in Interstitial Fluid and Venous Blood During Periods of Rapid Glucose Change”, Abbott Diabetes Care, Inc. Freestyle Navigator Continuous Glucose Monitor Pamphlet, 2004.
Isermann, R., “Supervision, Fault-Detection and Fault-Diagnosis Methods—An Introduction”, Control Engineering Practice, vol. 5, No. 5, 1997, pp. 639-652.
Isermann, R., et al., “Trends in the Application of Model-Based Fault Detection and Diagnosis of Technical Processes”, Control Engineering Practice, vol. 5, No. 5, 1997, pp. 709-719.
Johnson, P. C., “Peripheral Circulation”, John Wiley & Sons, 1978, pp. 198.
Jungheim, K., et al., “How Rapid Does Glucose Concentration Change in Daily Life of Patients with Type 1 Diabetes?”, 2002, pp. 250.
Jungheim, K., et al., “Risky Delay of Hypoglycemia Detection by Glucose Monitoring at the Arm”, Diabetes Care, vol. 24, No. 7, 2001, pp. 1303-1304.
Kaplan, S. M., “Wiley Electrical and Electronics Engineering Dictionary”, IEEE Press, 2004, pp. 141, 142, 548, 549.
Lortz, J., et al., “What is Bluetooth? We Explain the Newest Short-Range Connectivity Technology”, Smart Computing Learning Series, Wireless Computing, vol. 8, Issue 5, 2002, pp. 72-74.
Malin, S. F., et al., “Noninvasive Prediction of Glucose by Near-Infrared Diffuse Reflectance Spectoscopy”, Clinical Chemistry, vol. 45, No. 9, 1999, pp. 1651-1658.
McGarraugh, G., et al., “Glucose Measurements Using Blood Extracted from the Forearm and the Finger”, TheraSense, Inc., 2001, 16 Pages.
McGarraugh, G., et al., “Physiological Influences on Off-Finger Glucose Testing”, Diabetes Technology & Therapeutics, vol. 3, No. 3, 2001, pp. 367-376.
McKean, B. D., et al., “A Telemetry-Instrumentation System for Chronically Implanted Glucose and Oxygen Sensors”, IEEE Transactions on Biomedical Engineering, vol. 35, No. 7, 1988, pp. 526-532.
Pickup, J., et al., “Implantable Glucose Sensors: Choosing the Appropriate Sensing Strategy”, Biosensors, vol. 3, 1987/1988, pp. 335-346.
Pickup, J., et al., “In Vivo Molecular Sensing in Diabetes Mellitus: An Implantable Glucose Sensor with Direct Electron Transfer”, Diabetologia, vol. 32, 1989, pp. 213-217.
Pishko, M. V., et al., “Amperometric Glucose Microelectrodes Prepared Through Immobilization of Glucose Oxidase in Redox Hydrogels”, Analytical Chemistry, vol. 63, No. 20, 1991, pp. 2268-2272.
Quinn, C. P., et al., “Kinetics of Glucose Delivery to Subcutaneous Tissue in Rats Measured with 0.3-mm Amperometric Microsensors”, The American Physiological Society, 1995, E155-E161.
Roe, J. N., et al., “Bloodless Glucose Measurements”, Critical Review in Therapeutic Drug Carrier Systems, vol. 15, Issue 3, 1998, pp. 199-241.
Sakakida, M., et al., “Development of Ferrocene-Mediated Needle-Type Glucose Sensor as a Measure of True Subcutaneous Tissue Glucose Concentrations”, Artificial Organs Today, vol. 2, No. 2, 1992, pp. 145-158.
Sakakida, M., et al., “Ferrocene-Mediated Needle-Type Glucose Sensor Covered with Newly Designed Biocompatible Membrane”, Sensors and Actuators B, vol. 13-14, 1993, pp. 319-322.
Salehi, C., et al., “A Telemetry-Instrumentation System for Long-Term Implantable Glucose and Oxygen Sensors”, Analytical Letters, vol. 29, No. 13, 1996, pp. 2289-2308.
Schmidtke, D. W., et al., “Measurement and Modeling of the Transient Difference Between Blood and Subcutaneous Glucose Concentrations in the Rat After Injection of Insulin”, Proceedings of the National Academy of Sciences, vol. 95, 1998, pp. 294-299.
Shaw, G. W., et al., “In Vitro Testing of a Simply Constructed, Highly Stable Glucose Sensor Suitable for Implantation in Diabetic Patients”, Biosensors & Bioelectronics, vol. 6, 1991, pp. 401-406.
Shichiri, M., et al., “Glycaemic Control in Pancreatectomized Dogs with a Wearable Artificial Endocrine Pancreas”, Diabetologia, vol. 24, 1983, pp. 179-184.
Shichiri, M., et al., “In Vivo Characteristics of Needle-Type Glucose Sensor—Measurements of Subcutaneous Glucose Concentrations in Human Volunteers”, Hormone and Metabolic Research Supplement Series, vol. 20, 1988, pp. 17-20.
Shichiri, M., et al., “Membrane Design for Extending the Long-Life of an Implantable Glucose Sensor” Diabetes Nutrition and Metabolism, vol. 2, 1989, pp. 309-313.
Shichiri, M., et al., “Needle-type Glucose Sensor for Wearable Artificial Endocrine Pancreas”, Implantable Sensors for Closed-Loop Prosthetic Systems, Chapter 15, 1985, pp. 197-210.
Shichiri, M., et al., “Telemetry Glucose Monitoring Device With Needle-Type Glucose Sensor: A Useful Tool for Blood Glucose Monitoring in Diabetic Individuals”, Diabetes Care, vol. 9, No. 3, 1986, pp. 298-301.
Shichiri, M., et al., “Wearable Artificial Endocrine Pancreas With Needle-Type Glucose Sensor”, The Lancet, 1982, pp. 1129-1131.
Shults, M. C., et al., “A Telemetry-Instrumentation System for Monitoring Multiple Subcutaneously Implanted Glucose Sensors”, IEEE Transactions on Biomedical Engineering, vol. 41, No. 10, 1994, pp. 937-942.
Sternberg, R., et al., “Study and Development of Multilayer Needle-Type Enzyme-Based Glucose Microsensors”, Biosensors, vol. 4, 1988, pp. 27-40.
Thompson, M., et al., “In Vivo Probes: Problems and Perspectives”, Clinical Biochemistry, vol. 19, 1986, pp. 255-261.
Turner, A., et al., “Diabetes Mellitus: Biosensors for Research and Management”, Biosensors, vol. 1, 1985, pp. 85-115.
Updike, S. J., et al., “Principles of Long-Term Fully Implanted Sensors with Emphasis on Radiotelemetric Monitoring of Blood Glucose from Inside a Subcutaneous Foreign Body Capsule (FBC)”, Biosensors in the Body: Continuous in vivo Monitoring, Chapter 4, 1997, pp. 117-137.
Velho, G., et al., “Strategies for Calibrating a Subcutaneous Glucose Sensor”, Biomedica Biochimica Acta, vol. 48, 1989, pp. 957-964.
Wilson, G. S., et al., “Progress Toward the Development of an Implantable Sensor for Glucose”, Clinical Chemistry, vol. 38, No. 9, 1992, pp. 1613-1617.
Canadian Patent Application No. 2,683,721, Examiner's Report dated Mar. 17, 2015.
European Patent Application No. 08745799.0, Extended European Search Report dated Oct. 16, 2012.
PCT Application No. PCT/US2008/060273, International Preliminary Report on Patentability and Written Opinion of the International Searching Authority dated Oct. 29, 2009.
PCT Application No. PCT/US2008/060273, International Search Report and Written Opinion of the International Searching Authority dated Oct. 1, 2008.
U.S. Appl. No. 12/102,836, Notice of Allowance dated Jun. 18, 2010.
U.S. Appl. No. 12/102,836, Office Action dated Mar. 11, 2010.
U.S. Appl. No. 12/894,004, Notice of Allowance dated Apr. 7, 2011.
U.S. Appl. No. 12/894,004, Office Action dated Dec. 30, 2010.
U.S. Appl. No. 12/894,004, Office Action dated Jan. 21, 2011.
U.S. Appl. No. 13/114,029, Notice of Allowance dated Jan. 18, 2012.
U.S. Appl. No. 13/114,029, Office Action dated Nov. 2, 2011.
U.S. Appl. No. 13/437,894, Notice of Allowance dated Jan. 15, 2013.
U.S. Appl. No. 13/437,894, Office Action dated Oct. 17, 2012.
U.S. Appl. No. 13/867,948, Notice of Allowance dated Feb. 4, 2014.
U.S. Appl. No. 13/867,948, Office Action dated Dec. 16, 2013.
U.S. Appl. No. 13/867,948, Office Action dated Jul. 10, 2013.
U.S. Appl. No. 14/188,659, Notice of Allowance dated Nov. 26, 2014.
U.S. Appl. No. 14/188,659, Office Action dated Sep. 17, 2014.
U.S. Appl. No. 14/596,759, Notice of Allowance dated Apr. 20, 2016.
U.S. Appl. No. 14/596,759, Office Action dated Jan. 25, 2016.
U.S. Appl. No. 15/209,741, Office Action dated May 4, 2017.
U.S. Appl. No. 15/209,741, Notice of Allowance dated May 11, 2017.
Related Publications (1)
Number Date Country
20170354356 A1 Dec 2017 US
Provisional Applications (1)
Number Date Country
60911866 Apr 2007 US
Continuations (8)
Number Date Country
Parent 15209741 Jul 2016 US
Child 15686156 US
Parent 14596759 Jan 2015 US
Child 15209741 US
Parent 14188659 Feb 2014 US
Child 14596759 US
Parent 13867948 Apr 2013 US
Child 14188659 US
Parent 13437894 Apr 2012 US
Child 13867948 US
Parent 13114029 May 2011 US
Child 13437894 US
Parent 12849004 Aug 2010 US
Child 13114029 US
Parent 12102836 Apr 2008 US
Child 12849004 US